Integra Lifesciences Holdings (IART) Cash & Equivalents (2009 - 2026)

Integra Lifesciences Holdings' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $236.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 0.96% year-over-year to $236.8 million; the TTM figure through Mar 2026 stood at $236.8 million (down 0.96% YoY), while the FY2025 annual figure was $235.0 million, down 4.6% from the prior year.
• Cash & Equivalents came in at $236.8 million for Q1 2026 at Integra Lifesciences Holdings, up from $235.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $591.9 million in Q1 2024 to a low of $215.2 million in Q2 2024.
• A 5-year average of $318.8 million and a median of $273.7 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 92.57% in 2024 and plunged 59.61% in 2025, its largest moves.
• Integra Lifesciences Holdings' Cash & Equivalents stood at $456.7 million in 2022, then slumped by 39.47% to $276.4 million in 2023, then slipped by 10.86% to $246.4 million in 2024, then retreated by 4.6% to $235.0 million in 2025, then gained by 0.75% to $236.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $236.8 million, $235.0 million, and $232.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison